Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153174 · ClinicalTrials.gov registry record · Phase 1
Study of Sulphoraphane in Chronic Kidney Disease
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05153174 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 18 participants.
The verdict
NCT05153174, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of the compound sulforaphane that boosts the activity of antioxidant genes in the body to combat oxidative stress. Oxidative stress has been shown experimentally to play a role in kidney disease. This drug has been tested in patients with breast cancer who have normal kidney function, but has never been tested in patients with kidney disease. In this study, the investigators will establish a safe dose for patients with chronic kidney disease based on blood levels achieved in patients with normal kidney function.
Interventions
- DRUG Sulforaphane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05153174
The ClinicalTrials.gov registry entry for NCT05153174 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sulforaphane is the first listed.
NCT05153174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05153174 about?
NCT05153174 is a clinical study titled "Study of Sulphoraphane in Chronic Kidney Disease". The purpose of this study is to test the safety of the compound sulforaphane that boosts the activity of antioxidant genes in the body to combat oxidative stress. Oxidative stress has been shown experimentally to play a role in kidney disease. This drug has been tested in patients with breast cancer...
What is the current status of trial NCT05153174?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-05-02. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT05153174?
The interventions under investigation include: Sulforaphane (DRUG).
Who is sponsoring clinical trial NCT05153174?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.